Galera Therapeutics, Inc. · OTC:GRTX

Galera Therapeutics — Merger or Acquisition (April 2026)

17 slides from Galera Therapeutics's merger presentation, Apr 14, 2026

  1. Slide 1: Obsidian Therapeutics Corporate Deck April 2026

    Exhibit 99.2 Obsidian Therapeutics CORPORATE DECK APRIL 2026 © 2026 Obsidian Therapeutics Information Not Intended for Medical Communication

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, strategy and plans, industry environment,

  3. Slide 3: Obsidian Therapeutics: Regulatable mbIL15 for engineered TIL cell therapy

    Obsidian Therapeutics Harnessing protein regulation platform for engineered TIL cell therapy Lead Clinical 67% ORR Expansion Deep TIL Expertise, Program: at RP2D in to NSCLC Robust Investor OBX-115 Melanoma Syndicate • Novel, genetically • Differentiated safety • Building upon non- engineered TIL ce

  4. Slide 4: Harnessing Regulatable mbIL15 to Enhance OBX-115

    Harnessing Regulatable mbIL15 to Enhance OBX-115 Viral transduction of mbIL15-DRD OBX-115 or transgene Tumor Isolated Patient ACZ ligand TIL / cell cell therapy Unstable Unstable DRD DRD Degraded ACZ mbIL15 mbIL15 Proteasome ACZ-stabilized DRD mbIL15 Basal state On state ACZ, acetazolamide; DRD, dru

  5. Slide 5: Agni-01 Phase 1/2 Melanoma Patient Schema

    Agni-01 Phase 1/2 Melanoma Patient Schema Agni-01 Phase 1/2 Melanoma (N=23 Enrolled)* Phase 1 Phase 2 (N=11) (N=9) DL1 DL2 DL3/RP2D DL3/RP2D (N=3 ) (N=2) (N=6) (N=9) DL1 DL2 DL3/RP2D 9 9 9 30 × 10 100 × 10 100 × 10 OBX-115 cell cap cell cap cell cap 500 mg/day, 250 mg/day, 250 mg/day, Days 0–6, 14–2

  6. Slide 6: Regulatable mbIL15 Drives Differentiation vs Non-engineered TIL

    Obsidian Leverages Regulatable mbIL15 to Drive Comprehensive Differentiation vs Non‐ engineered TIL Transduced with regulatable mbIL15 • CD8+ cytotoxic, stem-like T cells with memory phenotype 67% ORR • ACZ (Diamox) to regulate mbIL15 More Convenient (n=10/15; incl. 2 CRs) expression Tissue Procurem

  7. Slide 7: OBX-115 Positioned Favorably vs Other 2L+ Advanced Melanoma Programs

    We Believe OBX-115 is Positioned Favorably vs Other 2L+ Adv Mel Programs OBX-115 AMTAGVI IMA203 RP1+Nivo Agni-01 Ph 2 ongoing Approved SUPRAME reg. trial ongoing CRL: April 2026 67% 7 8 9 Efficacy 31.5% 50% 33.6% mDOR: NR 6 ORR, DOR 8 of 10 responses mDOR: 36.5 mos mDOR: NR mDOR: 24.8 mos ongoing at

  8. Slide 8: Proprietary Manufacturing Process Potentially Enables Advantages

    Proprietary Manufacturing Process Potentially Enables Advantages in Phenotype, Yield, Process Control, and Procurement Method Ex Vivo Manufacturing Optimized Product: median >90% CD8+; effector- memory phenotype, stem-like signature, minimally 1,2 exhausted Tumor tissue Optimized Activation/ Optimiz

  9. Slide 9: Advancing OBX-115 to Registration-enabling Study

    Advancing OBX-115 to Registration-enabling Study • FDA feedback obtained on a single-arm trial design for accelerated approval (at Sponsor’s risk) for OBX-115 in patients with advanced melanoma progressing after ICI therapy ‒ Starting mid-2026, patients will be enrolled in registration-enabling Coho

  10. Slide 10: Key OBX-115 Melanoma Milestones Expected Through 2028

    Key OBX-115 Melanoma Milestones Expected Through 2028 Recent 2026 2027 2028 Achievements ü RP2D FDA engagement BLA submission: 2028 Registration-enabling study patients (Clinical & CMC): Q2 2026 fully enrolled : Q1 2027 enrolled Single-arm registration- Topline data: YE 2027 @ ü Pivotal enabling stu

  11. Slide 11: OBX-115 in NSCLC

    OBX-115 in NSCLC © 2026 Obsidian Therapeutics | 11

  12. Slide 12: OBX-115 Potential to Deliver Improved Product Profile in NSCLC

    OBX-115 Potential to Deliver Improved Product Profile in NSCLC OBX-115: Potential to Improve Lifileucel: Efficacy in 2L+ Lung, NSCLC TPP & Expand Market But Associated with Toxicity Risk Opportunity Lifileucel ORR in 2L+ Lung ü IL2-free regimen 30 25.6 21.4 ü Low-dose LD 20 N=39 ü Core needle biopsy

  13. Slide 13: NSCLC Dose Escalation Leveraged Melanoma Experience; Dose Optimization at DL3 Ongoing

    NSCLC Dose Escalation Leveraged Melanoma Experience; Dose Optimization at DL3 Ongoing Infused Patients* Melanoma NSCLC Phase 1 Phase 2 Phase 1 Dose Level (N=11) (N=9) (N=10) 30B cell dose cap ACZ: 250 mg/day, Days 0–13 DL1 3 0 1 ü Completed NSCLC dose escalation Planned 28-day cumulative dose: 3500

  14. Slide 14: Encouraging Signal at Intermediate Cell Dose Cap in NSCLC

    Following Early Monotherapy Signal in NSCLC, Encouraging Signal at Intermediate Cell Dose Cap with No Primary PD Ph 1 DL3 (n=3) Ph 1 Expansion DL3 (n=3) ACZ dose intensity 63% 29% 86% 86% 36% * 36% * (% planned dose received) OBX-115 dose 69.6 90.0 84.0 19.9 23.2 47.8 9 (cells × 10 ) Histology Non-s

  15. Slide 15: Galera's Portfolio

    Galera’s Portfolio Ongoing trial targeting Highly-Resistant forms of Advanced or Metastatic Breast Cancer Program Phase 1 Phase 2 Phase 3 Results Collaboration Houston Completed & Triple-Neg Breast Cancer (TNBC) Tilarginine Methodist 1 Published 35-pt Phase 1-2 combo trial Res. Inst + taxane 17% CR,

  16. Slide 16: Expected Clinical and Regulatory Catalysts

    Expected Clinical and Regulatory Catalysts Anticipated Milestones Melanoma RP2D data 1H 2026 Melanoma Top-Line data YE 2027 NSCLC Phase 1 data 1H 2027 Recent Achievements FDA clarity on Melanoma registrational Plan to continue manufacturing pathway and potency assay and process development RP2D enro

  17. Slide 17: Thank you

    Thank you © 2026 Obsidian Therapeutics Information Not Intended for Medical Communication

Galera Therapeutics — Merger or Acquisition (April 2026) on 6ix